Pilocarpine

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O

InChI

InChIKey=QCHFTSOMWOSFHM-WPRPVWTQSA-N

InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf

Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 160 Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11392632	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Head and neck cancer 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Secondary	Approved 8583	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Sjogren's syndrome 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Palliative	Approved 8583	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 1994
Open-angle glaucoma 53 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Ocular hypertension 52 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010
Acute angle-closure glaucoma 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8583	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
15 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
33 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	unhealthy, 44-75 years Health Status: unhealthy Age Group: 44-75 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	Disc. AE: Vision blurred... AEs leading to discontinuation/dose reduction: Vision blurred (moderate, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf
20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	Other AEs: Increased salivation, Lacrimation... Other AEs: Increased salivation (1 patient) Lacrimation (1 patient) Vomiting (1 patient) Anxiety (1 patient) Tremor (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf
1.54 % 3 times / day multiple, topical Recommended Dose: 1.54 %, 3 times / day Route: topical Route: multiple Dose: 1.54 %, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/

AEs

AE	Significance	Dose	Population
Vision blurred	moderate, 2 patients Disc. AE	2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	unhealthy, 44-75 years Health Status: unhealthy Age Group: 44-75 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf
Anxiety	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Increased salivation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Lacrimation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Tremor	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Vomiting	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years Health Status: unhealthy Age Group: 46 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/15093850

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP3A 227 CYP2D1 6	esterase 74 CYP2A6 626 CYP1A2 1197 CYP2C19 1119 CYP2E1 729 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP3A 317	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510190/pdf/brjpharm00164-0104.pdf#page=3 Page: 3.0	moderate
CYP2A6 911	inhibitor 4027 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes [Ki 1 uM]
CYP2D1 8	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572744/	yes [Ki 360 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C19 1119	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C9 1193	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2D6 1388	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2E1 729	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP3A4 1946	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/25755207/	yes
esterase 74	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes
CYP2A6 626	substrate 4014 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00GRLD	https://www.aablocks.com/goods/Goods/detail?id=AA00GRLD
abcr GmbH	AB167837	http://www.abcr.com/shop/en/AB167837
Acorn PharmaTech	ACN-035822	http://www.acornpharmatech.com/
Alfa Chemistry	AP92137	https://reagents.alfa-chemistry.com/product/pilocarpine-cas-92-13-7-18590.html
Alichem	69004656	http://www.alichem.com/en/products/92-13-7.html
Aurora Fine Chemicals LLC	A18.030.974	http://online.aurorafinechemicals.com/info?ID=A18.030.974
ChemMol	49426222	http://www.chemmol.com/chemmol/49426222.html
ChemMol	99173770	http://www.chemmol.com/chemmol/99173770.html
Chemspace	CSSB00016990803	https://chem-space.com/CSSB00016990803
Hairui	HR101326	http://www.hairuichem.com/en/product/54-71-7.html
Hairui	HR142167	http://www.hairuichem.com/en/product/92-13-7.html
Lab Network	LN00331142	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00331142
LGC Standards	DRE-A16208380AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16208380AL-100
LGC Standards	DRE-C16208380	https://www.lgcstandards.com/US/en/p/DRE-C16208380
mcule	MCULE-2634151840	https://mcule.com/MCULE-2634151840/
MolPort	MolPort-002-512-506	https://www.molport.com/shop/molecule-link/MolPort-002-512-506
OChem	12013	http://www.ocheminc.com/index.php?act=psearch&pid=092P137
R&D Chemicals	1835	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8154
Smolecule	S539680	http://www.smolecule.com/products/s539680
Smolecule	S772644	https://www.smolecule.com/products/s772644
THE BioTek	bt-278347	https://www.thebiotek.com/product/inhibitors/bt-278347
THE BioTek	bt-308560	https://www.thebiotek.com/product/others/bt-308560

PubMed

Title	Date	PubMed
Altered residual ATP content in rat brain cortex subcellular fractions following status epilepticus induced by lithium and pilocarpine.	1998 Dec	10344793
Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain.	1999	10443546
N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam.	1999	10430476
Loss of NADPH diaphorase-positive neurons in the hippocampal formation of chronic pilocarpine-epileptic rats.	1999	10401644
Growth-associated phosphoprotein expression is increased in the supragranular regions of the dentate gyrus following pilocarpine-induced seizures in rats.	1999	10366005
p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure.	1999 Aug 15	10436046
Inhibition of dentate granule cell neurogenesis with brain irradiation does not prevent seizure-induced mossy fiber synaptic reorganization in the rat.	1999 Jun 1	10341251
Effects of diazepam on extracellular brain neurotransmitters in pilocarpine-induced seizures in rats.	1999 Jun 4	10414434
Attenuation of focal adhesion kinase signaling following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate.	1999 Nov	10537051
Selective alterations of glycosaminoglycans synthesis and proteoglycan expression in rat cortex and hippocampus in pilocarpine-induced epilepsy.	1999 Nov 1	10582521
Differential regulation of cytokine expression following pilocarpine-induced seizure.	1999 Oct	10506506
Zinc inhibition of gamma-aminobutyric acid(A) receptor function is decreased in the cerebral cortex during pilocarpine-induced status epilepticus.	1999 Oct	10490925
Cognitive functions after pilocarpine-induced status epilepticus: changes during silent period precede appearance of spontaneous recurrent seizures.	1999 Sep	10487179
Infiltration of lymphocytes in the limbic brain following stimulation of subclinical cellular immunity and low dosages of lithium and a cholinergic agent.	1999 Sep 20	10514033
Patterns of status epilepticus-induced substance P expression during development.	2000	11074153
Similar increases in extracellular lactic acid in the limbic system during epileptic and/or olfactory stimulation.	2000	10828528
Differential progression of Dark Neuron and Fluoro-Jade labelling in the rat hippocampus following pilocarpine-induced status epilepticus.	2000	10771339
Nonconvulsive status epilepticus in rats: impaired responsiveness to exteroceptive stimuli.	2000 Dec 20	11099755
Motor and electrographic response of refractory experimental status epilepticus in rats and effect of calcium channel blockers.	2000 Feb	11218825
In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy.	2000 Nov	11205735
Rapid alterations in diffusion-weighted images with anatomic correlates in a rodent model of status epilepticus.	2000 Nov-Dec	11110536
Synchronized feeding as a "conditioned stimulus" for overt seizures in chronically (limbic) epileptic rats: a model for "psychogenic seizures" with complex partial epilepsy.	2001	11264918
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.	2001 Apr	11316102
2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats.	2001 Apr	11311893
Alkaline phosphatase activity in whitefly salivary glands and saliva.	2001 Apr	11304750
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy.	2001 Apr 17	11303773
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.	2001 Feb	11336078
Brief successive temporal observational sampling as a possible indicator of daily overt seizure activity in epileptic rats.	2001 Feb	11322611
The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension.	2001 Feb	11318298
Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma.	2001 Feb	11318297
An animal model of nonconvulsive status epilepticus: a contribution to clinical controversies.	2001 Feb	11240586
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.	2001 Feb	11181437
Regional and subunit-specific downregulation of acid-sensing ion channels in the pilocarpine model of epilepsy.	2001 Feb	11162239
Relationship between neuronal loss and interictal glucose metabolism during the chronic phase of the lithium-pilocarpine model of epilepsy in the immature and adult rat.	2001 Feb	11161611
The role of sensory signals from the insect coxa-trochanteral joint in controlling motor activity of the femur-tibia joint.	2001 Feb	11160496
Do recurrent febrile convulsions decrease the threshold for pilocarpine-induced seizures? Effects of nitric oxide.	2001 Feb 28	11248357
Uveal effusion after cataract surgery: an echographic study.	2001 Jan	11150272
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.	2001 Jan 1	11149716
Innervation of sweat glands in the forehead. A study in patients with Horner's syndrome.	2001 Jan 15	11166792
[Dry mouth].	2001 Jan 31	11252939
Visual discrimination learning impairments produced by combined transections of the anterior temporal stem, amygdala and fornix in marmoset monkeys.	2001 Jan 5	11146050
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.	2001 Jul	11431452
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil.	2001 Mar	11262695
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model.	2001 Mar	11259499
Reconstruction of an in vitro cornea and its use for drug permeation studies from different formulations containing pilocarpine hydrochloride.	2001 Mar	11226818
Reduced excitatory drive onto interneurons in the dentate gyrus after status epilepticus.	2001 Mar 15	11245688
Metabotropic glutamate receptor 8 in the rat hippocampus after pilocarpine induced status epilepticus.	2001 Mar 16	11226630
In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug.	2001 Mar-Apr	11253934
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland.	2001 May 1	11316558

Patents

Sample Use Guides

In Vivo Use Guide

Ophthalmic solution: Instill one drop in the eye(s) up to four times daily. Oral formulation: the recommended dose is 5 mg taken three times a day (Head and Neck Cancer Patients) or 5 mg taken four times a day (Sjogren's Syndrome Patients).

Route of Administration: Other

In Vitro Use Guide

Rat submandibular gland cells were treated wth 100 uM pilocarpine. The drug elicited a small and sustained increase in [Ca2+]i, indicating that pilocarpine acts as a partial agonist for mAChR-mediated Ca2+ responses.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:55:15 GMT 2025` Edited by `admin` on `Mon Mar 31 17:55:15 GMT 2025`
Record UNII	01MI4Q9DI3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Pilocarpine

Common Name

English

OCUSERT PILO

Preferred Name

English

PILOCARPINUM [HPUS]

Common Name

English

PILOCARPOL

Common Name

English

2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)-

Systematic Name

English

PILOCARPINE [USP MONOGRAPH]

Common Name

English

PILOCARPINE [MI]

Common Name

English

Pilocarpine [WHO-DD]

Common Name

English

PILOCARPINE [MART.]

Common Name

English

SPERSACARPINE

Common Name

English

OCUCARPINE

Common Name

English

PILOCARPINE [VANDF]

Common Name

English

PILOCARPINE [HSDB]

Common Name

English

PILOCARPINE [USP-RS]

Common Name

English

PILOCARPINE [ORANGE BOOK]

Common Name

English

PILOCARPINE [JAN]

Common Name

English

SYNCARPINE

Common Name

English

PILOKARPIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN07AX01